|Budget Amount *help
¥3,500,000 (Direct Cost : ¥3,500,000)
Fiscal Year 2003 : ¥1,300,000 (Direct Cost : ¥1,300,000)
Fiscal Year 2002 : ¥2,200,000 (Direct Cost : ¥2,200,000)
A newly-defined adult lymphoma entities have been analyzed in this study in order to reveal clinicopathologic and biologic profiles of newly-defined adult lymphoma entities, including de novo CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL), intravascular large B-cell lymphoma (IVL), and senile EBC-associated B-cell lymphoproliferative disorder (Senile EBV+ B-LPD). More than 100 cases were registered for constructing the data base in the future case-control clinical trial as the nation-wide multi-center study in CD5+ DLBCL and IVL, respectively. Simultaneously, the prognostic significance of their morphologic and phenotypic variants were clarified, implying their relatively broad spectrum. Senile EBV+ B-LPD were fires described in 2003 by us, sharing several properties with the immunodeficiency-associated lymphoproliferative disorder. This unique disease was assumed to be derived from the immunological deterioration by the aging itself, because most of the patients were more than 60years old with a median of 78 years. We are now concentrating much effort on this newly-recognized disease, which will be more prevalent in the near future, for clarifying the clinical finding and prognosis and developing the new strategies to the treatment and prevention.